MCSTAP Case Discussion Series: Terminating Treatment for SUD After Successful Treatment and Abstinence - October 16, 2024

This site is for learners who attended the live October 16, 2024, program to claim credit.

Claiming Credit 

Thank you for participating in this program. Once logged in, please click on "Take Course" on the right-hand side and your enrollment will be recorded. You will be prompted to complete the evaluation and claim your credit on the following page.

ADA statement: To request reasonable accommodations for a disability please contact [email protected], in writing, at least two weeks prior to the activity.

Target Audience

Primary care physicians, internists, family practice physicians, nurse practitioners, nurses, and physician assistants

Learning Objectives

Upon completion of this activity, participants will be able to:
  • Analyze the epidemiology and research on long-term substance use disorder (SUD) outcomes.
  • Define and differentiate key terms: “In remission,” Resolved,” “Relapse,” and “Lapse.”
  • Evaluate the advantages and disadvantages of indefinite treatment versus treatment termination during remission.
  • Make informed decisions about treatment termination for patients in long-term remission, considering individual needs and circumstances.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    • 1.00 MA Opioid Education Statement
  • 1.00 Participation
Course opens: 
10/16/2024
Course expires: 
12/16/2024
Rating: 
0
Zoom
United States
Christopher Shanahan, MD, MPH, FACP
MCSTAP Medical Director, CME Course Director
 
Rachel King, MD
Faculty
 
 
BU CCE Operations Manager: Naomi Moeller

In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program meets the criteria of the Massachusetts Board of Registration in Medicine for 1 hour of opioid education.

 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    • 1.00 MA Opioid Education Statement
  • 1.00 Participation
Please login or register to take this course.